Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Black Diamond Therapeutics, Inc. (BDTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update"
07/07/2023 4 RA CAPITAL MANAGEMENT, L.P. (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Bought 935,850 shares @ $5, valued at $4.7M
07/06/2023 4 Behbahani Ali (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Bought 1,000,000 shares @ $5, valued at $5M
07/03/2023 4 BIOTECH GROWTH N V (10% Owner) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Bought 1,000,000 shares @ $5, valued at $5M
06/30/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "BLACK DIAMOND THERAPEUTICS, INC. 15,000,000 Shares of Common Stock Underwriting Agreement",
"Black Diamond Therapeutics, Inc."
06/30/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/29/2023 4 BIOTECH GROWTH N V (10% Owner) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Bought 1,740,000 shares @ $5.4914, valued at $9.6M
06/29/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/28/2023 4 Epstein David M. (SEE REMARKS) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Sold 25,000 shares @ $6.7, valued at $167.5k
06/16/2023 4 Behbahani Ali (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 5,655 shares @ $2.1, valued at $11.9k
06/16/2023 4 DIXON WENDY L (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 5,119 shares @ $2.1, valued at $10.7k
06/16/2023 4 Velleca Mark A. (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 8,929 shares @ $2.1, valued at $18.8k
05/17/2023 4 Behbahani Ali (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 16,500 options to buy @ $1.82, valued at $30k
05/17/2023 4 Mayweg Alexander (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 16,500 options to buy @ $1.82, valued at $30k
05/17/2023 4 Shah Rajeev M. (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 16,500 options to buy @ $1.82, valued at $30k
05/17/2023 4 Velleca Mark A. (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 16,500 options to buy @ $1.82, valued at $30k
05/17/2023 4 Menzel Garry E (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 16,500 options to buy @ $1.82, valued at $30k
05/17/2023 4 Kulkarni Samarth (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 16,500 options to buy @ $1.82, valued at $30k
05/17/2023 4 DIXON WENDY L (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 16,500 options to buy @ $1.82, valued at $30k
05/17/2023 4 Dhingra Kapil (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 16,500 options to buy @ $1.82, valued at $30k
05/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update"
04/04/2023 ARS Form ARS - Annual Report to Security Holders:
04/04/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/04/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/20/2023 4 Behbahani Ali (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 7,111 shares @ $1.67, valued at $11.9k
03/20/2023 4 DIXON WENDY L (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.
Txns: Granted 6,437 shares @ $1.67, valued at $10.7k
03/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
Docs: "Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update"
12/23/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy